User login

Join The Debate

Cast your vote and join the conversation.

Membership is free.


Get Started

Error message

Notice: Undefined variable: html in _bfm_debates_streaming_debate_ticker_block() (line 828 of /var/www/vhosts/www.intelligencesquaredus.org/www/sites/all/modules/custom/bfm_debates/inc/bfm_debates.blocks.inc).

You are here

FDA considers controversial fertility procedure. What'€™s at stake?

FDA considers controversial fertility procedure. What'€™s at stake?

pdf (237.29 KB)

On Tuesday Feb. 25 and Wednesday Feb. 26, the FDA will consider a controversial cutting-edge fertility procedure otherwise known as '€œoocyte modification in assisted reproduction for the prevention of transmission of mitochondrial disease or treatment of infertility.'€ Despite the hype, the mitochondrial transfer procedures being considered are far from the '€œcreation of three-parent babies.'€

Instead, the FDA is finally considering whether it should green-light small clinical trials that could one day enable the thousands of women afflicted with mitochondrial disorders to have a shot at having healthy genetic children. Passions tend to run high in this area. Before the alarm bells start ringing on both sides, it might be helpful to have an overview of what is and is not at stake.

You can learn more about the pros and cons of mitochondrial transfer by listening to the Intelligence Squared Debate, in which I participated, here. It was a great debate and really aired a lot of the issues.